Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedSep 23, 2015Hydromorphone 50 mg/ml + Fentanyl 3Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1675-2015Class IITerminatedSep 23, 2015Hydromorphone 45 mg/ml + Fentanyl 10Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1674-2015Class IITerminatedSep 23, 2015Hydromorphone 35 mg/ml + Bupivacaine 4 mg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1673-2015Class IITerminatedSep 23, 2015Hydromorphone 35 mg/ml + Bupivacaine 10 mg/ml + Baclofen 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1672-2015Class IITerminatedSep 23, 2015Hydromorphone 3 mg/ml + Baclofen 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1671-2015Class IITerminatedSep 23, 2015Hydromorphone 20 mg/ml + Clonidine 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1670-2015Class IITerminatedSep 23, 2015Hydromophone 10 mg/ml + Clonidine 300 mcg/ml + Baclofen 120 mcg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1669-2015Class IITerminatedSep 23, 2015Calmme InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1668-2015Class IITerminatedSep 23, 2015Buckshot InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1667-2015Class IITerminatedSep 23, 2015Bi-Mix MediumLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1666-2015Class IITerminatedSep 23, 2015Bi-Mix (20/1) InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1665-2015Class IITerminatedSep 23, 2015Bi-Mix #1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1664-2015Class IITerminatedSep 23, 2015Zinc Chloride 25mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1663-2015Class IITerminatedSep 23, 2015Zinc 5 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1662-2015Class IITerminatedSep 23, 2015Vancomycin 25 mg/ml Ophthalmic SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1661-2015Class IITerminatedSep 23, 2015Testosterone 75 mg and B12 6 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1660-2015Class IITerminatedSep 23, 2015Testosterone 200 mg Anastrazole 9 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1659-2015Class IITerminatedSep 23, 2015Testosterone 200 mg Anastrazole 1 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1658-2015Class IITerminatedSep 23, 2015Testosterone 60 mg Anastrazole 4 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1657-2015Class IITerminatedSep 23, 2015Testosterone 80 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1656-2015Class IITerminatedSep 23, 2015Testosterone 75 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1655-2015Class IITerminatedSep 23, 2015Testosterone 72.5 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1654-2015Class IITerminatedSep 23, 2015Testosterone 70 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1653-2015Class IITerminatedSep 23, 2015Testosterone 62.5 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1652-2015Class IITerminatedSep 23, 2015Testosterone 50 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1651-2015Class IITerminatedSep 23, 2015Testosterone USPLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1650-2015Class IITerminatedSep 23, 2015Testosterone Propionate 100 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1649-2015Class IITerminatedSep 23, 2015Testosterone USP Aqueous 200 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1648-2015Class IITerminatedSep 23, 2015Testosterone Enanthate 200 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1647-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 200 mg/ml Anastrazole 0.25 mg/ml Cholecalciferol 50Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1646-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 200 mg/ml Anastrazole 2 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1645-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 200 mg/ml Anastrazole 0.5 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1644-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 200 mg/ml Anastrazole 0.25 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1643-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 200mg/ml Injection Multi-Dose VialLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1642-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 150 mg/ml Injection Multi-Dose VialLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1641-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 100 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1640-2015Class IITerminatedSep 23, 2015SUPER LIPO InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1639-2015Class IITerminatedSep 23, 2015Sufentanil 50 mcg/ml + Bupivacaine 0.25 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1638-2015Class IITerminatedSep 23, 2015Sufentanil 50 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1637-2015Class IITerminatedSep 23, 2015Sufentanil 45 mcg/ml + Bupivacaine 5 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1636-2015

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.